# Blockade of Presynaptic α2δ1−2 Subunits of Voltage-Gated Ca²⁺ Channels Attenuates Neurobiochemical and Sensorimotor Deficits After Traumatic Brain Injury in Mice

**Authors:** Jijo S. Justus, Marcelo S. Rodolphi, Afonso Kopczynski, Nathan R. Strogulski, Gabriela C. S. Herasinczuk, Bruna Valdameri, Christian Limberger, Cesar A. Geller, Lucia H. Vinadé, Chariston Dal-Belo, Wagner L. Nedel, Luiz O. C. Portela, Vitória G. de Oliveira, Douglas H. Smith, Luis V. Portela

PMC · DOI: 10.1007/s11064-026-04729-3 · 2026-03-25

## TL;DR

Blocking presynaptic α2δ1-2 subunits with pregabalin reduces brain injury effects in mice, improving neurological and motor outcomes.

## Contribution

Demonstrates that targeting presynaptic α2δ1-2 subunits mitigates TBI-induced neurodegeneration and sensorimotor deficits in mice.

## Key findings

- Pregabalin reduced glutamate levels and improved mitochondrial calcium handling after TBI.
- Treatment decreased neurodegeneration markers like caspase-3 and Tau hyperphosphorylation.
- Pregabalin improved sensorimotor function and neurological severity scores in injured mice.

## Abstract

Traumatic brain injury (TBI) to the motor cortex disrupts corticospinal tracts and induces persistent sensorimotor impairments, largely driven by secondary neurobiochemical cascades. Excessive synaptic glutamate release, mitochondrial Ca²⁺ overload, and progressive neurodegeneration critically shape these outcomes, with preclinical and clinical data revealing neuronal loss and proteinopathy resembling motor neuron disorders. Here, we investigated whether pregabalin blockade of the presynaptic α2δ1-2 subunit of voltage-gated Ca²⁺ channels could mitigate excitotoxicity and promote sensorimotor recovery after TBI. Mice subjected to controlled cortical impact (CCI) received daily pregabalin (i.p., 60 mg.kg-1) or saline for 10 days, and neurobehavioral performance was assessed at 24 h, 11-, and 12-days post-injury. In addition to robust and persistent deficits detected by the modified neurological severity score (mNSS), complementary tests including open field, grip strength, cylinder, wire-hanging, and inverted screen, captured sensitive impairments in corticospinal integrity and global motor function. Pregabalin treatment downregulated α2δ2 subunit expression, reduced cerebrospinal fluid glutamate levels, and restored mitochondrial Ca²⁺ handling by improving influx–efflux dynamics through Na⁺/Ca²⁺ exchange. At the molecular level, pregabalin decreased hallmarks of neurodegeneration, including Cyclin dependent kinase 5, TauSer396 hyperphosphorylation, caspase-12, and caspase-3 within synaptic terminals. These neuroprotective effects translated into significant improvements in both mNSS and multidimensional sensorimotor outcomes following TBI. Together, our findings confirm the neurodegenerative trajectory underlying TBI-induced neuromotor deficits and highlight the presynaptic α2δ1–2 subunit antagonism as a promising therapeutic target to mitigate long-term neurological sequelae.

The online version contains supplementary material available at 10.1007/s11064-026-04729-3.

## Linked entities

- **Proteins:** Caspase-12 (caspase-12), Casp3 (caspase 3)
- **Chemicals:** pregabalin (PubChem CID 4715169), glutamate (PubChem CID 611)
- **Diseases:** traumatic brain injury (MONDO:0858950)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mcu (mitochondrial calcium uniporter) [NCBI Gene 215999] {aka 2010012O16Rik, C10orf42, Ccdc109a, D130073L02Rik, Gm64}, Casp12 (caspase 12) [NCBI Gene 12364], Car2 (carbonic anhydrase 2) [NCBI Gene 12349] {aka CAII, Ca2, Car-2, Ltw-5, Lvtw-5}, Tomm20 (translocase of outer mitochondrial membrane 20) [NCBI Gene 67952] {aka 1810060K07Rik, Gm19268, MAS20, MOM19, TOM20, mKIAA0016}, Cacna2d2 (calcium channel, voltage-dependent, alpha 2/delta subunit 2) [NCBI Gene 56808] {aka Cacna2d, a2d2, du, mKIAA0558, td, torpid}, CACNA2D2 (calcium voltage-gated channel auxiliary subunit alpha2delta 2) [NCBI Gene 9254] {aka CACNA2D, CASVDD}, Tyms (thymidylate synthase) [NCBI Gene 22171] {aka Ts}, Rac1 (Rac family small GTPase 1) [NCBI Gene 363875], Cdk5 (cyclin dependent kinase 5) [NCBI Gene 12568] {aka Crk6}, App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Slc8b1 (solute carrier family 8 (sodium/lithium/calcium exchanger), member B1) [NCBI Gene 170756] {aka NCKX6, NCLX, Slc24a6}
- **Diseases:** stroke (MESH:D020521), impaired muscle strength (MESH:D009135), axonal injury (MESH:D001480), contralateral (MESH:C535634), ataxia (MESH:D001259), synaptic (MESH:D012183), TS (MESH:D014947), bleeding (MESH:D006470), neuromotor impairments (MESH:D060825), proteinopathy (MESH:D057165), epilepsy (MESH:D004827), Brain Injury (MESH:D001930), neurovascular dysfunction (MESH:D013901), brain lesion (MESH:D001927), sensorimotor (MESH:D020233), motor disability (MESH:D009069), depression (MESH:D003866), asymmetry (MESH:D005146), infarct (MESH:D007238), tumor (MESH:D009369), aggression (MESH:D010554), toxicity (MESH:D064420), Neurofunctional Deficits (MESH:C564098), muscle (MESH:D019042), Hemorrhagic CSF (MESH:D002559), pain (MESH:D010146), motor deficits (MESH:D009461), appetite loss (MESH:D001068), excitotoxic damage (MESH:D020263), brain edema (MESH:D001929), cortex (MESH:D000303), fibromyalgia (MESH:D005356), Na+ channelopathy (MESH:D053447), neurotoxic (MESH:D020258), Cortical Injury (MESH:D054220), neuroinflammation (MESH:D000090862), spinal cord injury (MESH:D013119), neurobehavioral deficits (MESH:D019954), impaired locomotor activity (MESH:D001523), mitochondrial dysfunction (MESH:D028361), TBI (MESH:D000070642), anxiety (MESH:D001007), head injury (MESH:D006259), motor dysfunction (MESH:D000068079), axonal degeneration (MESH:D009410), CCI (MESH:D004834), glutamate (MESH:C537425), motor neuron disorder (MESH:D016472), Neurological Impairments (MESH:D009422), vomiting (MESH:D014839), functional deficits (MESH:D001289), paresis (MESH:D010291), spasticity (MESH:D009128), Neurodegeneration (MESH:D019636), unconsciousness (MESH:D014474), CS (MESH:C536209), CNS injury (MESH:D002493)
- **Chemicals:** PVDF (MESH:C024865), Calcium (MESH:D002118), succinate (MESH:D019802), Na+ (MESH:D012964), PA595536;1:10000 (-), gabapentin (MESH:D000077206), mercaptoethanol (MESH:D008623), memantine (MESH:D008559), Pregabalin (MESH:D000069583), isoflurane (MESH:D007530), Percoll (MESH:C016039), methanol (MESH:D000432), Glutamate (MESH:D018698), Glutamine (MESH:D005973), KCl (MESH:D011189), alcohol (MESH:D000438), sucrose (MESH:D013395), pyruvate (MESH:D019289), sodium dihydrogen phosphate (MESH:C018279), MK-801 (MESH:D016291), ADP (MESH:D000244), polyacrylamide (MESH:C016679), mannitol (MESH:D008353), CaCl2 (MESH:D002122), EDTA (MESH:D004492), malate (MESH:C030298), HEPES (MESH:D006531), T60 (MESH:C077099), N2 (MESH:D009584), NaCl (MESH:D012965), NMDA (MESH:D016202), o-phthalaldehyde (MESH:D009764), C60 (MESH:C069837)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** CF — Homo sapiens (Human), Cystic fibrosis, Embryonic stem cell (CVCL_A239), AB3613 — Homo sapiens (Human), Bare lymphocyte syndrome type 2, Transformed cell line (CVCL_B7K5)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13018067/full.md

---
Source: https://tomesphere.com/paper/PMC13018067